Daewon Pharm
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more
Daewon Pharm (003220) - Total Liabilities
Latest total liabilities as of September 2025: ₩342.50 Billion KRW
Based on the latest financial reports, Daewon Pharm (003220) has total liabilities worth ₩342.50 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Daewon Pharm - Total Liabilities Trend (2011–2024)
This chart illustrates how Daewon Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Daewon Pharm Competitors by Total Liabilities
The table below lists competitors of Daewon Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Verkkokauppa.com Oyj
HE:VERK
|
Finland | €140.74 Million |
|
Krishana Phoschem Limited
NSE:KRISHANA
|
India | ₹8.26 Billion |
|
Unibel S.A
PA:UNBL
|
France | €2.65 Billion |
|
Fineotex Chemical Limited
NSE:FCL
|
India | ₹898.43 Million |
|
Shenzhen L&A Design Holding Limited
SHE:300949
|
China | CN¥578.16 Million |
|
Barton Gold Holdings Ltd
AU:BGD
|
Australia | AU$14.80 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Daewon Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daewon Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daewon Pharm (2011–2024)
The table below shows the annual total liabilities of Daewon Pharm from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩298.81 Billion | +22.60% |
| 2023-12-31 | ₩243.73 Billion | +19.02% |
| 2022-12-31 | ₩204.78 Billion | -3.03% |
| 2021-12-31 | ₩211.18 Billion | +72.47% |
| 2020-12-31 | ₩122.44 Billion | -0.71% |
| 2019-12-31 | ₩123.32 Billion | +33.69% |
| 2018-12-31 | ₩92.24 Billion | +56.15% |
| 2017-12-31 | ₩59.07 Billion | +12.16% |
| 2016-12-31 | ₩52.67 Billion | +14.28% |
| 2015-12-31 | ₩46.09 Billion | -0.04% |
| 2014-12-31 | ₩46.11 Billion | +24.99% |
| 2013-12-31 | ₩36.89 Billion | +7.86% |
| 2012-12-31 | ₩34.20 Billion | -6.23% |
| 2011-12-31 | ₩36.47 Billion | -- |